Aptevo Therapeutics INC S-1 registration statements

Aptevo Therapeutics entered a $60 million standby equity purchase agreement with YA II PN, LTD., registering shares for resale while advancing its cancer immunotherapy pipeline.

Aptevo Therapeutics Inc. filed an S-1 registration statement for the resale of up to 6.9 million common shares by YA II PN, LTD., part of a $25 million standby equity purchase agreement to fund its clinical-stage biotechnology pipeline.

Aptevo Therapeutics Inc. has filed an S-1 registration statement to allow a selling stockholder to resell up to 8.25 million shares, enabling the company to potentially raise up to $25 million through a Standby Equity Purchase Agreement to fund its clinical-stage oncology pipeline.

Aptevo Therapeutics Inc. has filed a Rule 462(b) registration statement to register an additional $67,500 in securities, including common stock and warrants, for its ongoing public offering.

Aptevo Therapeutics Inc. has initiated a public offering of common stock and warrants to raise approximately $7.2 million, while simultaneously addressing significant financial challenges including a shareholders' deficit and Nasdaq listing non-compliance, despite reporting positive clinical trial results for its lead cancer candidates.

Aptevo Therapeutics is registering for resale up to 3,529,420 shares of common stock issuable upon the exercise of common stock purchase warrants.

Aptevo Therapeutics launches a public offering of common stock and warrants to raise capital for clinical programs and general corporate purposes.

Aptevo Therapeutics is launching a public offering of common stock, pre-funded warrants, and common stock purchase warrants to raise capital for working capital and general corporate purposes.

Aptevo Therapeutics launches a public offering of common stock and warrants, aiming to raise capital for working capital and general corporate purposes, including the further development of its product candidates.

Aptevo Therapeutics is launching a public offering to sell up to 8,000,000 shares of common stock, pre-funded warrants, and various series of warrants to raise capital for working capital and general corporate purposes.

Aptevo Therapeutics is launching a public offering to sell shares of common stock, pre-funded warrants, and common warrants to raise capital for working capital and general corporate purposes.

Aptevo Therapeutics is launching a public offering to sell shares of common stock, pre-funded warrants, and common warrants, aiming to raise capital for clinical programs and general corporate purposes.

Aptevo Therapeutics is launching a public offering of common stock and warrants to raise capital for clinical programs and general corporate purposes.

Aptevo Therapeutics is launching a public offering to sell shares of common stock, pre-funded warrants, and common warrants to raise capital for working capital and general corporate purposes.

Aptevo Therapeutics is launching a public offering of common stock and warrants to raise capital for its clinical programs and general corporate purposes, focusing on advancing its immunotherapy candidates for cancer treatment.

Aptevo Therapeutics is launching a public offering of common stock and warrants to raise capital for clinical programs and general corporate purposes.

Aptevo Therapeutics is launching a public offering to sell shares of common stock, pre-funded warrants, and common warrants to raise capital for working capital and general corporate purposes.